Chemo + ADT + RT: no benefit after 10 years

Earlier this month, we looked at the evidence of benefit for adding chemotherapy to androgen deprivation therapy (ADT) + radiation therapy (RT) for high-risk prostate cancer (see “Docetaxel with radiation in prostate cancer treatment”). … READ MORE …

Survival benefit of dose escalation for higher risk patients

As discussed in a previous article, there is a seeming discrepancy between the findings of Kalbasi et al. and RTOG 0126, at least for intermediate-risk patients. … READ MORE …

Rotating shift work and risk for prostate cancer

There have been suggestions in the past that people who work shifts, cycling between day and night work, may be at higher risk for various cancers than people who do regular daytime work. … READ MORE …

New trial of investigational immunotherapy in men on active surveillance

There appears to be a high degree of confidence that Barvarian Nordic’s Prostvac will show positive results in the ongoing Phase III clinical trial in men with metastatic, castration-resistant prostate cancer. An early stage trial has now been initiated among men with much less advanced disease disease. … READ MORE …

Genetic risk, aggressive prostate cancer, and ethnic/racial differences

According to a newly published article in the Journal of Clinical Oncology, there are new and strong indications that a specific “genomic fingerprint” is associated with elevated risk for diagnosis of aggressive prostate cancer in African Americans compared to Caucasians. … READ MORE …

Standardizing outcome measures in management of advanced prostate cancer

The Advanced Prostate Cancer Working Group of the International Consortium for Health Outcomes Measurement has finally been able to pull together a set of standardized patient-centered outcomes relevant to the evaluation of men in treatment for advanced forms of prostate cancer. … READ MORE …

Statins as agents to reduce risk for prostate cancer

In the past few years we have become used to seeing data from a range of studies suggesting that ongoing statin therapy is associated with both a lowered risk for diagnosis with prostate cancer and beneficial impact on the outcomes of treatment for prostate cancer once diagnosed. However, … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,343 other followers